Cwm LLC Has $209,000 Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Cwm LLC cut its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 17.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 625 shares of the medical research company’s stock after selling 134 shares during the quarter. Cwm LLC’s holdings in Bio-Rad Laboratories were worth $209,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Fulton Bank N.A. bought a new stake in Bio-Rad Laboratories during the third quarter valued at $224,000. RK Asset Management LLC bought a new stake in shares of Bio-Rad Laboratories during the 3rd quarter valued at about $5,198,000. GAMMA Investing LLC grew its stake in Bio-Rad Laboratories by 66.7% during the third quarter. GAMMA Investing LLC now owns 535 shares of the medical research company’s stock worth $179,000 after purchasing an additional 214 shares during the period. Handelsbanken Fonder AB increased its holdings in Bio-Rad Laboratories by 20.6% in the third quarter. Handelsbanken Fonder AB now owns 5,272 shares of the medical research company’s stock worth $1,764,000 after purchasing an additional 900 shares in the last quarter. Finally, Paragon Capital Management Inc. acquired a new position in Bio-Rad Laboratories in the second quarter valued at approximately $1,309,000. Institutional investors own 65.24% of the company’s stock.

Insider Activity at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the sale, the executive vice president now owns 147 shares of the company’s stock, valued at $48,582.03. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, COO Andrew J. Last sold 3,000 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the sale, the chief operating officer now owns 7,559 shares of the company’s stock, valued at approximately $2,494,016.46. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the transaction, the executive vice president now owns 147 shares in the company, valued at approximately $48,582.03. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 17.06% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on BIO. StockNews.com downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Wells Fargo & Company began coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price objective on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $401.00 target price on shares of Bio-Rad Laboratories in a research report on Friday, August 16th. Finally, Citigroup upgraded Bio-Rad Laboratories from a “neutral” rating to a “buy” rating and increased their price target for the stock from $350.00 to $400.00 in a report on Tuesday, October 1st. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $368.20.

Bio-Rad Laboratories Trading Down 0.9 %

Shares of BIO opened at $340.10 on Wednesday. Bio-Rad Laboratories, Inc. has a twelve month low of $261.59 and a twelve month high of $364.24. The stock has a market cap of $9.70 billion, a PE ratio of -32.83 and a beta of 0.95. The company has a quick ratio of 4.63, a current ratio of 6.28 and a debt-to-equity ratio of 0.18. The business’s 50-day moving average price is $330.87 and its 200-day moving average price is $307.14.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Thursday, August 1st. The medical research company reported $3.11 earnings per share for the quarter, topping the consensus estimate of $2.12 by $0.99. Bio-Rad Laboratories had a negative net margin of 51.73% and a positive return on equity of 3.77%. The company had revenue of $638.50 million for the quarter, compared to analysts’ expectations of $645.79 million. During the same period in the prior year, the business earned $3.00 earnings per share. Bio-Rad Laboratories’s revenue for the quarter was down 6.3% compared to the same quarter last year. On average, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 9.45 EPS for the current fiscal year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.